文献速递新发突发、热带与寄生虫病

东南欧地方性虫媒病毒病住院成人的患病率、临床管理与结局(MERMAIDS-ARBO):一项前瞻性观察性研究

Prevalence, clinical management, and outcomes of adults hospitalised with endemic arbovirus illness in southeast Europe (MERMAIDS-ARBO): a prospective observational study.
PubMed 文献 · Lancet Infect Dis · 2025-02-20

这项前瞻性观察性研究在东南欧7国21家医院连续4个虫媒病毒季节纳入929例疑似虫媒病毒感染的住院成人,最终847例纳入分析,110例(13%)确诊或 probable 急性虫媒病毒感染,其中西尼罗病毒53例(6%)、托斯卡纳病毒44例(5%)、蜱传脑炎病毒16例(2%)、克里米亚-刚果出血热病毒1例(<1%),仅1例死亡(<1%)。住院期间80%使用抗生素、42%使用糖皮质激素、24%使用抗病毒药,12%需重症监护,中位住院9天。

要点

  • 847例分析人群中110例(13%)确诊或 probable 急性虫媒病毒感染,西尼罗病毒占53例(6%)。
  • 住院成人中80%接受抗生素、42%接受糖皮质激素、24%接受抗病毒药,12%需重症监护。
  • 110例虫媒病毒感染者中仅49例(45%)出院诊断为临床医生归因的虫媒病毒感染。

核心结论

  • 数据凸显需加强虫媒病毒监测系统以早期发现新发再发暴发,包括提高临床医生认知、改善专科诊断可及性、研发有效可及的疫苗和治疗。

研究设计与样本

  • 前瞻性观察性研究(MERMAIDS-ARBO),2016-19年每年5月1日至10月31日四个虫媒病毒季节,在东南欧7国21家医院纳入症状出现21天内住院、年龄≥18岁且符合虫媒病毒兼容疾病综合征的成人。
  • 排除非感染性中枢神经系统疾病、其他明确病因症状、明确局灶感染源或基础疾病复发所致症状者;筛查2896例,招募929例,913例符合方案定义资格标准。

主要发现

  • 913例中位年龄43.1岁(IQR 29.5-59.7),550例(60%)男性、361例(40%)女性、2例(<1%)数据缺失;530例(58%)表现为疑似脑膜炎、脑炎或两者兼有,318例(35%)表现为发热伴肌痛、发热伴关节痛或两者兼有。
  • 820例(90%)报告症状出现前21天内无国际旅行;727例(80%)使用抗生素、379例(42%)使用糖皮质激素、222例(24%)使用抗病毒药;中位住院9天(IQR 6-14),113例(12%)需重症监护。
  • 847例符合完整分析资格且有参考实验室样本的参与者中,110例(13%)诊断114例次确诊或 probable 急性虫媒病毒感染(4例合并感染或交叉反应):CCHFV 1例(<1%)、TBEV 16例(2%)、TOSV 44例(5%)、WNV 53例(6%);WNV感染者中1例死亡(<1%)。
  • 110例虫媒病毒感染者中49例(45%)出院诊断为当地临床医生归因的虫媒病毒感染。

关键数值与推荐

  • 确诊或 probable 急性感染依据参考实验室标准判定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Arboviruses have expanded into new regions in Europe, yet data indicate gaps in disease notifications and a risk of further spread. We aimed to report on prevalence, clinical management, and outcomes of endemic arbovirus infections in southeast Europe. METHODS: In this prospective observational study (MERMAIDS-ARBO), we enrolled adults (age ≥18 years) hospitalised with an arbovirus-compatible disease syndrome within 21 days of symptom onset across 21 hospitals in seven countries in southeast Europe over four arbovirus seasons (May 1-Oct 31, during 2016-19). We obtained data from case report forms completed by site investigators on admission and discharge. Participants were excluded if they had non-infectious CNS disorders, symptoms of another confirmed cause, an identified focal source of infection, or symptoms caused by recurrence of a pre-existing condition. The primary outcome was the proportion of participants with confirmed or probable acute infections with West Nile virus (WNV), tick-borne encephalitis virus (TBEV), Crimean-Congo haemorrhagic fever virus (CCHFV), or Toscana virus (TOSV), per reference laboratory criteria. Secondary outcomes were the proportions of patients treated with antivirals, antibiotics, or corticosteroids; the proportion of patients requiring intensive care; hospital length of stay; and mortality. FINDINGS: Of 2896 adults screened for eligibility, 929 were recruited and 913 met protocol-defined eligibility criteria (median age 43·1 years [IQR 29·5-59·7]; 550 [60%] men, 361 [40%] women, and two [<1%] with missing data). 530 (58%) participants presented with suspected meningitis, encephalitis, or both, and 318 (35%) with fever plus myalgia, fever plus arthralgia, or both. 820 (90%) reported no international travel within 21 days before symptom onset. 727 (80%) were administered antibiotics, 379 (42%) corticosteroids, and 222 (24%) antivirals. The median length of hospital stay was 9 days (IQR 6-14), and 113 (12%) required intensive care. Of 847 participants with a reference laboratory sample who met full eligibility criteria for analysis, 110 (13%) were diagnosed with 114 confirmed or probable acute arbovirus infections (four had coinfections or cross-reactivity): one (<1%) with CCHFV, 16 (2%) with TBEV, 44 (5%) with TOSV, and 53 (6%) with WNV. There was one death (<1%) of an individual with WNV. Of the 110 participants, 49 (45%) had a local clinician-attributed arbovirus discharge diagnosis. INTERPRETATION: Our data highlight the need to strengthen arbovirus surveillance systems for the early detection of emerging and re-emerging outbreaks, including investments to increase awareness of arbovirus infections among clinicians, to improve access to specialist diagnostics, and to develop effective and accessible vaccines and treatments to protect populations and health systems in southeast Europe. FUNDING: European Commission and Versatile Emerging infectious disease Observatory. TRANSLATIONS: For the Greek, Albanian, Romanian, Bosnian, Serbian, and Croatian translation of the summary see Supplementary Materials section.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Sigfrid L, Chan XHS, Kasbergen LMR, et al. Prevalence, clinical management, and outcomes of adults hospitalised with endemic arbovirus illness in southeast Europe (MERMAIDS-ARBO): a prospective observational study. Lancet Infect Dis. 2025. PMID: 39987929. doi:10.1016/S1473-3099(24)00655-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。